Threshold Pharmaceuticals Announces Completion of Patient Recruitment for Phase 2 TH-302 Pancreatic Cancer Study

Threshold Pharmaceuticals, Inc. THLD, announced today the completion of patient enrollment into the Company's Phase 2 pancreatic cancer study with TH-302, a novel small molecule tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia and is applicable to a broad range of solid tumors. Enrollment in the study exceeded initial recruitment expectations. As a result, the company expanded the study's enrollment target from the original 165 patients to at least 200 patients, consequently increasing the statistical power of the study to greater than 80%.